Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21015259 | 0.86 | HRH3 (0.37) | HSD11B1MAOBHRH3 | |
| SCHEMBL15183638 | 0.82 | HSD11B1 (0.39) | HSD11B1SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL24800863 | 0.79 | CACNA1I (0.31) | — | |
| SCHEMBL14330956 | 0.79 | PKM (0.34) | HSD11B1MEN1KMT2AKDM4EKDM1A | |
| SCHEMBL20076499 | 0.79 | DRD2 (0.38) | MEN1KMT2A | |
| SCHEMBL19573431 | 0.79 | RAB9A (0.38) | KDM4E | |
| SCHEMBL4893194 | 0.78 | HSD11B1 (0.47) | HSD11B1MEN1KMT2AGBA1MAP4K4 | |
| SCHEMBL6057032 | 0.78 | — | — | |
| SCHEMBL8149011 | 0.78 | HSD11B1 (0.47) | HSD11B1MEN1KMT2AGBA1MAP4K4 | |
| SCHEMBL21348335 | 0.78 | ALDH1A1 (0.42) | MEN1KMT2AHRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2018-04-19 | — | — | US | disclosed |
| US-9890198-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2018-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | FKBP5, FKBP1B, MALT1 | HSD11B1 190/4885SLC6A4 501/4885SLC6A3 1365/4885 |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | HSD11B1 237/4885SLC6A4 544/4885SLC6A3 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.